

# RSC Advances



This article can be cited before page numbers have been issued, to do this please use: B. Chalyk, I. Kandaurova, K. Hrebeniuk, O. Manoilenko, I. Kulik, R. Iminov, V. Kubyshkin, A. Tverdokhlebov, P. K. Mykhailiuk and O. Ablialimov, *RSC Adv.*, 2016, DOI: 10.1039/C6RA02365G.



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

## A base promoted multigram synthesis of aminoisoxazoles: valuable building blocks for drug discovery and peptidomimetics.

Bohdan A. Chalyk,<sup>a</sup> Inna Y. Kandaurova,<sup>b</sup> Kateryna V. Hrebeniuk,<sup>b</sup> Olga V. Manoilenko,<sup>a</sup> Irene B. Kulik,<sup>d</sup> Rustam T. Iminov,<sup>a</sup> Vladimir Kubyshkin,<sup>e</sup> Anton V. Tverdokhlebov,<sup>a\*</sup> Osman K. Abliyalimov,<sup>a\*</sup> and Pavel K. Mykhailiuk<sup>a,c,f\*</sup>

<sup>a</sup>Enamine Ltd., Chervonotkatska 78, 01103 Kyiv, Ukraine, [www.enamine.net](http://www.enamine.net)

[A.tverdohlebov@mail.enamine.net](mailto:A.tverdohlebov@mail.enamine.net) (AT),

[O.abliyalimov@mail.enamine.net](mailto:O.abliyalimov@mail.enamine.net) (OA),

[Pavel.Mykhailiuk@gmail.com](mailto:Pavel.Mykhailiuk@gmail.com), [Pavel.Mykhailiuk@mail.enamine.net](mailto:Pavel.Mykhailiuk@mail.enamine.net) (PM)


<sup>b</sup>Department of Chemistry, Kyiv Polytechnic Institute, Prosp. Peremohy 37, Kyiv 03056, Ukraine.

<sup>c</sup>Department of Chemistry, Taras Shevchenko National University of Kyiv, Volodymyrska Street 64, Kyiv 01601, Ukraine

<sup>d</sup>Institute of Bioorganic Chemistry & Petrochemistry, NAS of Ukraine, Murmanska 1, Kyiv 02660, Ukraine

<sup>e</sup>Institute of Chemistry, Technical University of Berlin, Müller-Breslau-Str. 10, Berlin 10623, Germany

<sup>f</sup>UkrOrgSyntez Ltd. (UORSY), Chervonotkatska 78, 01103 Kyiv, Ukraine, [www.uorsy.com](http://www.uorsy.com)



### Abstract


A practical multigram metal free synthesis of isoxazole-containing building blocks from commercially available amino acids was elaborated. The key reaction was a regioselective [3+2]-cycloaddition of *in situ*-generated nitrile oxides with alkynes/enamines. The obtained building blocks were used in the preparation of bioactive compounds and peptidomimetics.

### Keywords

Isoxazole, [3 + 2]-cycloaddition, nitrile oxides, building blocks, drug discovery.

## Introduction

Isoxazole core is a structural element in many commercial pharmaceuticals (Figure 1). The range of biological activities of the isoxazole-containing drugs is broad: analgesic,<sup>1</sup> anti-inflammatory,<sup>1a,c,2</sup> anthelmintic,<sup>3</sup> anti-depressant,<sup>4</sup> anti-bacterial,<sup>5</sup> anticancer,<sup>6</sup> insecticidal,<sup>7</sup> nootropic,<sup>8</sup> anxiolytic,<sup>8a</sup> neuroprotective,<sup>9</sup> and HIV-inhibitory agents.<sup>10</sup> In this context, the development of practical methods towards isoxazole-based building blocks from common cheap starting materials is truly desirable.



**Figure 1.** Commercialized biologically active derivatives of isoxazole.

Nitrile oxides are useful intermediates towards the synthesis of a wide plethora of isoxazole-based architectures.<sup>11a-h</sup> However; most of these methods either utilize toxic metals or hypervalent iodine compounds<sup>11h</sup> which in turn, are not environmentally friendly. At the same time, there are just a few known reports dealing with *metal-free* conditions and most common are based on the use of triethylamine<sup>12a-b</sup> and sodium perchlorate/triethylamine.<sup>12c</sup> Therefore, the development of *metal-free* protocols towards the synthesis of compounds bearing isoxazole core are of particular interest.<sup>12d</sup>

The use of amino acids<sup>13a-h</sup> in construction of isoxazole-containing compounds has been known before. However, these reports, dealt with the specific amino acids, and the studies have not been performed systematically on large variety of substrates. Taking into account the need of exploration of *metal-free* protocols as well as search for easily available substrates, herein we would like to elaborate on a general practical multigram

*metal-free* synthesis of isoxazole-core building blocks starting from commonly available and diverse  $\alpha$ -,  $\beta$ - and  $\gamma$ -amino acids.


## Results and discussion

### Synthesis

**1. Synthesis of chloroximes from amino acids.** The initial synthesis step was reduction of the amino acid carboxyl-groups in a number of N-Boc protected amino acids. Resulting N-Boc amino alcohols were subsequently oxidized into the corresponding aldehydes (Table 1). These aldehydes formed oximes upon treatment with hydroxylamine under mildly basic conditions (sodium hydrogencarbonate). The oximes were then treated with *N*-chlorosuccinimide under acidic conditions to afford the target N-Boc protected chloroximes **1-7** in good yields. The products were white powders that could be stored at room temperature for at least several months as exemplified in Table 1.

**Table 1.** Chloroximes synthesized starting from N-Boc amino acids.

Boc-amino acid			Chloroxime	Yield <sup>a</sup>	Storage <sup>b</sup>
Boc-Gly		<b>1</b>		49%	>2 years
Boc-(S)-Ala		<b>2</b>		68%	≤0.5 years <sup>c</sup>
Boc-(R)-Ala		<b>3</b>		67%	≤0.5 years <sup>c</sup>
Boc-(S)-Pro		<b>4</b>		70%	>2 years
Boc-(R)-Pro		<b>5</b>		71%	>2 years



<sup>a</sup> Overall yield over four steps. <sup>b</sup> The products were stored in closed flasks at the room temperature. <sup>c</sup> The products were stored at 0 °C under argon. After six months *ca.* 10% decomposition was found according to <sup>1</sup>H NMR.

## 2. Synthesis of *N*-Boc aminoisoxazoles via [3+2]-cycloaddition.


It is worth mentioning that our methodology for the synthesis of variety isoxazoles is known and here we would just mention some selected examples where the similar conditions like base or reaction temperatures were applied. Johnson et al reported on the regioselective synthesis of 3,4-disubstituted isoxazoles between enolsilanes and nitrile oxides.<sup>14</sup> In the same vein, the Zhu group and later Wang and co-workers reported on the synthesis of 3,4-disubstituted isoxazoles in high yields.<sup>15a,b</sup> The key point of the reported protocols was the reaction of *in situ* generated enamines from corresponding ketones or  $\beta$ -keto esters and nitrile oxides. Caddick and co-workers reported an interesting strategy towards the synthesis of 3,5-disubstituted isoxazoles bearing sulfonamide group at the 5-position.<sup>16</sup> Later the Shibata group developed the strategy for the synthesis of isoxazole triflones.<sup>17</sup> Hamme et al reported on the synthesis of 3,5-disubstituted isoxazoles with electron withdrawing group at the 5-position by the reaction of 1,1-disubstituted bromoalkenes with nitrile oxides.<sup>18a,b</sup> Last but not least Schmidt and co-workers reported on the regioselective synthesis of 4-trifluorosubstituted isoxazoles in good yields.<sup>19</sup> All the aforementioned methods avoided the usage of metal-mediated reactions which prompted us to follow the similar conditions in order to synthesize a large panel of aminoisoxazoles in large scale.

In our case, synthesis of isoxazoles from the corresponding *in situ*-generated nitrile oxides and alkynes/enamines was analogous to the mentioned above methods. Namely, treatment of chloroximes **1-7** with a mild base (sodium hydrogen carbonate or triethylamine) at either the room temperature or at 0 °C generated corresponding nitrile oxides (Table 2). Subsequent addition of enamines **8-10** (1.2 eq) to these *in situ* generated nitrile oxides lead to [3+2]-cycloaddition intermediates that readily eliminated dimethylamine to give the 3,4-disubstituted isoxazoles in a regioselective fashion as previously reported with push-pull enamines (Table 2, A).<sup>20</sup> In contrast, terminal alkynes

**11**, **12** afforded a mixture of 3,4-/3,5-isomers ~30/70 when reaction was performed at the room temperature.<sup>21</sup> Nevertheless, the same reaction at 0 °C exhibited an improved regioselectivity of ~10/90, and the major 3,5-disubstituted isomers were easily isolated by column chromatography.<sup>22</sup>

While the above described [3+2] cycloaddition reactions were performed in ethyl acetate the synthesis also worked well in tetrahydrofuran, dichloromethane, dimethoxymethane or chloroform, though with compromised regioselectivity. At the same time synthesis of isoxazoles in water as environmentally benign solvent is of high interest.<sup>23</sup> It is also worth mentioning, that these reactions were performed under obligatory high dilution – substrate/solvent = 1/10 (wt:v), – otherwise formation of side furoxans was observed.<sup>24</sup>

As the result we obtained a variety of N-Boc aminoisoxasoles initially starting from amino acids, and the synthetic approach was scalable such that up to 50 g of a product (Boc-**6**-H) was obtained in a single synthesis run.

**Table 2.** The synthesis of N-Boc aminoisoxazoles via [3+2]-cycloaddition.


<sup>a</sup> Et<sub>3</sub>N was used instead of NaHCO<sub>3</sub> to generate the nitrile oxide, 5 eq. of **12** were used.

### 3. Synthesis of isoxazole-containing amines and amino acids.

We also made several forays toward the cleavage of TMS-group utilizing K<sub>2</sub>CO<sub>3</sub> or trifluoroacetic acid (TFA) as TMS-scavengers,<sup>25</sup> but unfortunately in our case the described procedure was not that effective, furnishing the desired products in moderate yields. Moreover, attempts to cleave TMS-group with 4M HCl in dioxane were also not so effective in terms of low yield. Though, these forays were not successful, it allowed us to improve


our tactics. As a result, we found that cleavage of the TMS-group from the isoxazole core was easily achieved by treatment with catalytic amounts of  $\text{KHF}_2$  in methanol – water mixture. Resulting 3-substituted isoxazoles were obtained in excellent yields (Table 3).

**Table 3.** Cleavage of TMS-group from the isoxazole ring.




As next, cleavage of N-Boc group from all compounds was performed under acidic conditions to afford the target building blocks – aminoisoxazoles (Table 4).




**Table 4.** Cleavage of the N-Boc protection group from the amino moiety.

Carboxymethyl-substituted isoxazoles were saponificated with sodium hydroxide in methanol to afford corresponding free amino acids in good yields (Table 5).

**Table 5.** Synthesis of isoxazole-containing amino acids.

The structures of two final compounds were confirmed by X-ray analysis (Figure 2). Interestingly, the structure of Boc-4A-COMe indicates a repulsion occurring between the carbamate carbonyl oxygen and the isoxazole nitrogen, similar to what has been recently reported for analogous structures with 1,3-oxa/thiazine in place of the isoxazole.<sup>26</sup>


**Figure 2.** X-ray crystal structures of Boc-4A-COMe and Boc-6A-CO<sub>2</sub>H.

### Practical applications.

After having established a practical general synthetic protocol towards isoxazole-containing building blocks, we also aimed to demonstrate applicability of the synthesized structures in other chemical areas.


**1. Synthesis of a drug candidate.** **ABT-418** is a known nootropic agent.<sup>27a</sup> Recently, chemists at *Abbott Laboratories* synthesized its bioisostere **16** in four steps and 7.3% total yield starting from **4** and 2-bromopropene.<sup>27b</sup> Herein, we have developed an alternative approach to afford compound **16** (Scheme 1). First, [3+2]-cycloaddition between

allylbromide and nitrile oxide generated from chloroxime **4** gave isoxazoline **13** in 95 % yield. Next, elimination of hydrogen bromide under basic conditions gave isoxazole **14**. Cleavage of the N-Boc group produced free amine **15**, which was subjected to reductive amination with aqueous formaldehyde to afford the target product **16** in gram quantities. The overall yield of the synthesis was 55% over 5 steps.



**Scheme 1.** Synthesis of isoxazole **16** – bioisostere of the known nootropic agent **ABT- 418**.

**2. Synthesis of peptidomimetics.** We also envisioned that chiral aminoisoxazoles could be used to prepare conformationally restricted peptidomimetics.<sup>28</sup> In this case the heterocyclic fragment will act as a rigid peptide bond substitute<sup>29</sup> (Scheme 2).




**Scheme 2.** (a)  $\alpha$ -peptide, and its conformationally-restricted analogue with isoxazole backbone; (b) construction of a post-translationally modified peptide with oxa/thiasole backbone.

In addition, isomeric oxazoles and thiazoles are common in the backbones<sup>30</sup> of various ribosomally synthesized and post-translationally modified peptides.<sup>31</sup> Construction of an azole ring is generally afforded in nature by cyclization of serine or threonine side chain on the downstream amide bond.<sup>32,33,34</sup> Total synthesis of respective peptidomimetics has been developed in order to provide naturally occurring antimicrobial agents or toxins as well as their chemically modified analogues.<sup>35,36</sup> Though, oxa/thiazole to isoxazole mutations have not been explored. Therefore, next we attempted the synthesis of

isoxazole-containing peptidomimetics by solid phase peptide synthesis (SPPS) in order to highlight this opportunity.

Initially we synthesized the Fmoc-protected amino acid Fmoc-AlaIso-OH (**17**) (Scheme 3). Peptide chains were grown on Rink-amide resin, and TBTU/HOBt/DIPEA system was used for coupling. Only in the case of Ac-Leu-AlaIso-Val-NH<sub>2</sub> (**18**) we observed minor degree of epimerization ( $\leq 15\%$ ), whereas in Ac-Leu-Val-AlaIso-NH<sub>2</sub> (**19**) no racemization was observed.<sup>37</sup> In addition, no degradation was found after cleavage from the resin upon treatment with TFA/TIS. Generally the amino acid Fmoc-AlaIso-OH turned out to be compatible with the standard SPPS, allowing synthesis and isolation of both target peptides by conventional methods.<sup>38</sup>



**Scheme 3.** Synthesis of isoxazole-containing peptidomimetics **18** and **19**.

## Conclusions

We have developed a general *metal-free* practical protocol towards isoxazole-containing building blocks starting from commonly available  $\alpha$ -,  $\beta$ - and  $\gamma$ -amino acids. The target products were obtained in up to 50 g scale. The high potential of the developed method was demonstrated by synthesis of compound **16** – bioisostere of the known nootropic agent **ABT-418**, - and preparation of isoxazole-containing peptidomimetics **18**, **19** by solid phase peptide synthesis.

## Experimental Section.

**General:** All reagents were available from Enamine Ltd. Solvents were purified according to standard procedures. When organic solutions were concentrated under reduced pressure, 35–40 °C bath temperature was used. Column chromatography was performed with silica gel 60 (230–400 mesh) as the stationary phase.  $^1\text{H}$ ,  $^{13}\text{C}$  NMR spectra were recorded at the NMR spectrometers operating at 400 and 500  $^1\text{H}$  frequency (101 and 126 MHz for  $^{13}\text{C}$  experiments). NMR chemical shifts are reported in ppm, in the  $\delta$  scale and are referenced using residual NMR solvent peaks at 7.26 and 77.16 ppm for  $^1\text{H}$  and  $^{13}\text{C}$  in  $\text{CDCl}_3$ , 2.50 and 39.52 ppm for  $^1\text{H}$  and  $^{13}\text{C}$  in  $\text{DMSO}-d_6$ , for 4.79 and  $^1\text{H}$  in  $\text{D}_2\text{O}$ . For peptides NMR analysis was performed in 5 mM peptide solutions in  $\text{CD}_3\text{OD}$  at 700 MHz ( $^1\text{H}$  frequency) spectrometer.  $^1\text{H}$  NMR spectra were recorded 25 min after the peptides were dissolved (fresh) and therefore contained few of the non-exchanged amide resonances. The  $^1\text{H}$  NMR spectra were in addition recorded after overnight measurements when the NH-to-ND exchange was already completed.  $^1\text{H}$  HOHAHA (dipsi2 of 60 ms) and ROESY (spin-lock 300 ms) spectra were recorded to complete the assignment of the  $^1\text{H}$  resonances.  $^{13}\text{C}$   $\{^1\text{H}\}$  dept45 and  $^1\text{H}$   $\{^{13}\text{C}\}$  HSQC experiments were performed in order to assign accompanied  $^{13}\text{C}$  resonances. The following abbreviations are used in reported NMR data: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad), brs (broad singlet). Coupling constants (J) are in Hz. Spectra are reported as follows: chemical shift ( $\delta$ , ppm), multiplicity, integration, coupling constants (Hz). Measured melting points are uncorrected. Boiling points were measured at 0.8 mm Hg unless otherwise specified herein. LC-MS data were acquired on Agilent 1200 HPLC system equipped with DAD/ELSD/LCMS-6120 diode-matrix and mass-selective detector, column: Poroshell 120 SB-C18, 4.6 mm  $\times$  30 mm. Eluent, A, acetonitrile – water with 0.1 % of FA (99 : 1); B, water with 0.1% of FA. Optical rotations were measured on polarimeter in methanol using 1-dm cell; optical rotation values are given in  $10^{-1} \text{ deg cm}^2 \text{ g}^{-1}$ ; concentrations (c) are given in mmol/L, wavelength 589 nm at 20 °C. The enantiomeric excess and retention time ( $t_R$ ) was determined for major signal by HPLCs: Daicel CHIRALPACK IA, 5  $\mu\text{m}$ , 4.6 $\times$ 250 mm, Daicel CHIRALPACK IB, 5  $\mu\text{m}$ , 4.6 $\times$ 250 mm, Daicel CHIRALPACK OJ-H, 5  $\mu\text{m}$ , 4.6 $\times$ 250 mm, Daicel CHIRALPACK AS-H, 5  $\mu\text{m}$ , 4.6 $\times$ 250 mm chiral columns, injection volume 0.1  $\mu\text{L}$ , eluent (hexanes : 2-propanol). Solid compounds were recrystallized from acetonitrile unless other is specified.

## Synthesis of 3,4-disubstituted isoxazoles, representative procedure

### *methyl 3-(((tert-butoxycarbonyl)amino)methyl)isoxazole-4-carboxylate (Boc-1A-CO<sub>2</sub>Me)*

A 250 mL round bottomed flask was charged with a magnetic stirrer, corresponding chloroxime **1** (2 g, 9.6 mmol) and EtOAc (20 mL). To the resulting vigorously stirred homogeneous solution (*E*)-methyl 3-(dimethylamino) acrylate **8** (1.48 g, 11.5 mmol) was added followed by addition of NaHCO<sub>3</sub> (1.6 g, 19.2 mmol) at the ambient temperature. The resulting mixture was stirred overnight. The progress of the reaction was monitored by NMR spectroscopy. After the reaction was complete, the organic phase was washed with 10% NaHSO<sub>4(aq)</sub> (3×5 mL), 10% K<sub>2</sub>CO<sub>3(aq)</sub> (2×5 mL) and brine (1×5 mL). Organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The resulting mixture was filtered through a silicagel pad and concentrated to yield **Boc-1A-CO<sub>2</sub>Me** (95%, 2.3 g) as a beige powder, mp 65 °C. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 9.59 (s, 1H, *isoxaz*), 7.24 (brs, 1H, *NH*), 4.41 (d, 2H, *CH*<sub>2</sub>), 3.80 (s, 3H, *OCH*<sub>3</sub>), 1.39 (s, 9H, *CH*<sub>3</sub>-*Boc*). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>): δ 164.9, 161.1, 160.0, 155.4, 111.9, 78.2, 51.9, 35.9, 28.1. **MS** (APCI) *m/z* [M-Boc+1H]<sup>+</sup> calculated for C<sub>10</sub>H<sub>13</sub>N<sub>2</sub>O<sub>5</sub>: 255.1; found: 255.4. Anal. calcd for C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O<sub>5</sub>: C, 51.56; H, 6.29; N, 10.93. Found: C, 51.35; H, 6.07; N, 10.52.

## Synthesis of 3,5-disubstituted isoxazoles, representative procedure

### *methyl 3-(((tert-butoxycarbonyl)amino)methyl)isoxazole-5-carboxylate (Boc-1B-CO<sub>2</sub>Me)*

A 250 mL round bottomed flask was charged with a magnetic stirrer, corresponding chloroxime **1** (2 g, 9.6 mmol) and EtOAc (20 mL). Then, the resulting vigorously stirred homogeneous solution was cooled to -5 – 0 °C and methyl propiolate (0.9 mL, 10.1 mmol) was added followed by addition of NaHCO<sub>3</sub> (1.6 g, 19.2 mmol). (In case of reaction **7** (2 g, 7.6 mmol) with ethynyltrimethylsilane **12** (5.4 mL, 38 mmol) dropwise addition of Et<sub>3</sub>N (1.6 mL, 11.5 mmol) as a solution in EtOAc (100 mL) was required). The resulting mixture was stirred overnight. The progress of the reaction was monitored by NMR spectroscopy. Work-up was done by simple filtration through silica pad, then the resulting solution was concentrated and dried in *vacuo* to yield the corresponding product **Boc-1B-CO<sub>2</sub>Me** (89%,

2.2 g) as a white powder, mp 84-86 °C. For reaction of compound **7** with **12** when the reaction was complete, the organic phase was washed with 10% K<sub>2</sub>CO<sub>3(aq)</sub> (2×20 mL) and brine (1×20 mL). Organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 7.49 (s, 1H, *NH*), 7.05 (s, 1H, *isoxaz*), 4.24-4.23 (d, 2H, *J* = 5.5, *CH*<sub>2</sub>), 3.89 (s, 3H, *OCH*<sub>3</sub>), 1.39 (br, 9H, *CH*<sub>3</sub>-*Boc*). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>): δ 163.7, 159.5, 156.7, 155.7, 109.0, 78.5, 52.9, 35.6, 28.1. **MS** (APCI) *m/z* [M-*Boc*+1H]<sup>+</sup> calculated for C<sub>10</sub>H<sub>13</sub>N<sub>2</sub>O<sub>5</sub>: 255.1; found: 255.4. Anal. calcd for C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O<sub>5</sub>: C, 51.56; H, 6.29; N, 10.93. Found: C, 51.27; H, 6.54; N, 10.63.

### Representative procedure for cleavage of *tert*-butoxycarbonyl group

#### 1-(3-(aminomethyl)isoxazol-4-yl)ethan-1-one hydrochloride (**1A-COMe•HCl**)

A 250 mL round bottomed flask was charged with a magnetic stirrer, corresponding Boc-protected isoxazole **Boc-1A-COMe** (2.5 g, 9.8 mmol) and EtOAc (25 mL). The flask was submerged into an ice cooling bath; and to the vigorously stirred homogeneous solution equimolar ratio of MeOH (1.05 eq) was added followed by dropwise addition of AcCl (1.05 eq). As the result white precipitate was formed. After the reaction was complete (NMR control) resulting solid was filtered and washed with cold EtOAc and recrystallized from MeCN (if it was necessary) affording **1A-COMe•HCl** as a white powder. In case of EWG = CO<sub>2</sub>Me-group AcCl (1.05 eq) in MeOH was used.

**1A-COMe•HCl**: 95%, white powder, mp 94-96 °C. <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O-*d*<sub>2</sub>): δ 9.53 (s, 1H, *isoxaz*), 4.54 (s, 2H, *CH*<sub>2</sub>), 2.60 (s, 3H, *CH*<sub>3</sub>Ac). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>): δ 192.0, 166.1, 155.9, 119.8, 34.4, 29.0. **MS** (APCI) *m/z* [M+1H]<sup>+</sup> calculated for C<sub>6</sub>H<sub>9</sub>N<sub>2</sub>O<sub>2</sub>: 141.1; found: 141.2. Anal. calcd for C<sub>6</sub>H<sub>9</sub>ClN<sub>2</sub>O<sub>2</sub>: C, 40.81; H, 5.14; N, 15.86. Found: C, 40.25; H, 5.33; N, 15.96.

### Representative procedure for the hydrolysis of isoxazole-based esters

#### 3-(((*tert*-butoxycarbonyl)amino)methyl)isoxazole-4-carboxylic acid (**Boc-1A-CO<sub>2</sub>H**)

A 250 ml round bottomed flask was charged with a magnetic stirrer, corresponding isoxazole (**Boc-1A-CO<sub>2</sub>Me**, 2 g, 7.8 mmol) and MeOH (18 mL). Next, the flask was submerged into an ice cooling bath and to the resulting vigorously stirred homogeneous



solution 2 equiv. of 10% NaOH<sub>(aq)</sub> was added dropwise. After the NMR control indicated the reaction completion (10 – 24 h), the solution was concentrated in *vacuo*. HCl<sub>(aq)</sub>, or NaHSO<sub>4(aq)</sub>, was added dropwise until pH = 3 was reached and solid NaCl was added until the resulting solution become saturated. The product was extracted by EtOAc (3×20 mL). Combined organic fractions were dried over anhydrous MgSO<sub>4</sub>, concentrated and dried in *vacuo* yielding **Boc-1A-CO<sub>2</sub>H** as a white powder, (95%, 1.8 g), mp 129-131 °C. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 13.25 (br, 1H, C-OOH), 9.45 (s, 1H, *isoxaz*), 7.17 (brs, 1H, *NH-major rotamer*), 6.80 (brs, *NH-minor of rotamer*), 4.40 (d, 2H, *J* = 4.5, CH<sub>2</sub>), 1.38 (s, 9H, CH<sub>3</sub>-Boc). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>): δ 164.6, 162.4, 160.3, 155.5, 113.2, 78.2, 36.1, 28.2. **MS** (APCI) *m/z* [M-1H]<sup>+</sup> calculated for C<sub>10</sub>H<sub>13</sub>N<sub>2</sub>O<sub>5</sub>: 241.1; found: 241.2. Anal. calcd for C<sub>10</sub>H<sub>14</sub>N<sub>2</sub>O<sub>5</sub>: C, 49.58; H, 5.83; N, 11.56. Found: C, 49.38; H, 5.66; N, 11.43.

### Representative procedure for the for the synthesis of 3-substituted isoxazoles

#### *tert-butyl (isoxazol-3-ylmethyl)carbamate (Boc-1-H)*

A round bottomed flask (100 mL) was charged with a magnetic stirrer, substrate **Boc-1-H-TMS** (5.5 g, 20.3 mmol) and MeOH (25 mL). KHF<sub>2</sub> 5 mol% (80 mg, 1 mmol) with H<sub>2</sub>O<sub>(cat)</sub> (100 μL) were added and the resulting homogeneous solution was vigorously stirred for 24 h at the ambient temperature while the progress was monitored by NMR spectroscopy. After the reaction was completed the solvent was evaporated and the remaining residue was dissolved in EtOAc (50 mL). Organic phase was filtered through anhydrous Na<sub>2</sub>SO<sub>4</sub> pad and concentrated to yield **Boc-1-H** as a white powder (94%, 3.8 g.). <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ 8.79 (m, 1H, *CH-isoxaz*), 7.43-7.35 (brs, 1H, *NH*), 6.42 (s, 1H, *isoxaz*), 4.20-4.19 (m, 2H, CH<sub>2</sub>), 1.39 (s, 9H, CH<sub>3</sub>-Boc). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>): δ 161.5, 159.8, 155.7, 103.8, 78.3, 35.5, 28.2. Anal. calcd for C<sub>9</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>: C, 54.53; H, 7.12; N, 14.13. Found: C, 54.36; H, 7.18; N, 14.01.

### Synthesis of the ABT- 418 bioisostere 16

#### *tert-butyl (2S)-2-(5-(bromomethyl)-4,5-dihydroisoxazol-3-yl)pyrrolidine-1-carboxylate (13)*

A 500 mL round bottomed flask was charged with a magnetic stirrer, corresponding chloroxime **4** (10 g, 40.2 mmol) and EtOAc (100 mL). To the resulting vigorously stirred homogeneous solution allyl bromide (5.6 g, 46.23 mmol) was added followed by addition of



NaHCO<sub>3</sub> (6.7 g, 80.4 mmol). The resulting mixture was stirred overnight. The progress of the reaction was monitored by NMR spectroscopy. After the reaction was complete, organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered through the silica gel pad. The resulting solution was concentrated to yield **13** (95 %, 12.95 g) as a white powder, mp 60 °C.

**13-S-isomer**: 95%, white powder,  $[\alpha]_D^{20} = -80.00$  (*c* = 35.42). 99.6% ee, *t<sub>R</sub>* = 12.2 min;

**13-R-isomer**: 97%, white powder,  $[\alpha]_D^{20} = +81.84$  (*c* = 35.42), 99.8% ee, *t<sub>R</sub>* = 10.5 min.

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ 4.85-4.78 (m, 1H, *isoxazoline-CH*), 4.63 (brs, 1H, *-pyrrolidine-CH*), 3.48-3.32 (m, 4H, *CH<sub>2</sub>-pyrrolidine* + *CH<sub>2</sub>-Br*), 2.94-2.90 (m, 2H, *CH<sub>2</sub>-isoxazoline*), 2.17-1.91 (m, 4H, *CH<sub>2</sub>-pyrrolidine*), 1.46 (s, 9H, *CH<sub>3</sub>-Boc*). **<sup>13</sup>C NMR** (125 MHz, DMSO-*d*<sub>6</sub>, mixture of both rotamers): δ 160.3, 159.7, 153.5, 153.1, 78.8, 78.3, 54.0, 46.3, 46.0, 38.7, 35.7, 35.2, 34.8, 30.4, 30.2, 29.6, 29.3, 28.0, 23.9, 23.0. **MS** (APCI) *m/z* [M-Boc]<sup>+</sup> calculated for C<sub>8</sub>H<sub>13</sub>BrN<sub>2</sub>O: 235.0; found: 235.1. Anal. calcd for C<sub>13</sub>H<sub>21</sub>BrN<sub>2</sub>O<sub>3</sub>: C, 46.86; H, 6.35; N, 8.41. Found: C, 46.77; H, 6.44; N, 8.57.

#### ***tert-butyl (S)-2-(5-methylisoxazol-3-yl)pyrrolidine-1-carboxylate (14)***

A 250 mL round bottomed flask was charged with a magnetic stirrer, corresponding isoxazoline **13** (12.5 g, 37.5 mmol) and DMF (50 mL). K<sub>2</sub>CO<sub>3</sub> (10.4 g, 75 mmol) was added and the resulting mixture was stirred overnight at 100 °C. The progress of the reaction was monitored by NMR spectroscopy. After the reaction was complete, the reaction mixture was concentrated the residue was poured into ice-bath and aqueous phase was extracted with EtOAc. The combined organic phases were washed with brine (4×20 mL). Organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The resulting mixture was filtered through the silicagel pad and the solution was concentrated. The residue is colorless oil which was solidified upon standing 77%.

**14-S-isomer**: 77%,  $[\alpha]_D^{20} = -78.8$  (*c* = 3.96), 99.9% ee, *t<sub>R</sub>* = 9.5 min;

**14-R-isomer**: 75%,  $[\alpha]_D^{20} = +79.63$  (*c* = 3.96), 99.9% ee, *t<sub>R</sub>* = 7.6 min.

**<sup>1</sup>H NMR** (500 MHz, DMSO-*d*<sub>6</sub>): δ 6.10 (brs, 1H, *isoxaz*), 4.83-4.77 (m, 1H, *CH-pyrrolidine*), 3.43-3.38 (m, 2H, *CH<sub>2</sub>-pyrrolidine*), 2.36 (s, 3H, *CH<sub>3</sub>*), 2.21 (br, 1H, *CH-pyrrolidine*), 1.85 (br, 3H, *CH-pyrrolidine*), 1.39, (s, 9H, *CH<sub>3</sub>-Boc, major rotamer*), 1.24 (s, 9H, *CH<sub>3</sub>-Boc*,

*minor rotamer*).  $^{13}\text{C}$  NMR (125 MHz, DMSO- $d_6$ ):  $\delta$  169.02, 166.4, 166.0, 153.5, 153.2, 100.4, 99.8, 78.6, 78.5, 53.3, 53.1, 46.3, 46.0, 32.6, 31.3, 28.1, 27.9, 23.6, 22.9, 11.7.

**MS** (APCI)  $m/z$   $[\text{M}+3\text{H}]^+$  calculated for  $\text{C}_{13}\text{H}_{23}\text{N}_2\text{O}_3$ : 255.3; found: 255.2. Anal. calcd for  $\text{C}_{13}\text{H}_{20}\text{N}_2\text{O}_3$ : C, 61.88; H, 7.99; N, 11.10. Found: C, 61.95; H, 7.83; N, 11.14.

### **(S)-5-methyl-3-(pyrrolidin-2-yl)isoxazole hydrochloride (15\*HCl)**

The same experimental procedure as previously described for 3,4- and 3,5-analogues for the cleavage of Boc-group was used.

**15-S-isomer**, white powder, 92%,  $[\alpha]_D^{20} = -21.63$  ( $c = 53.00$ );

**15-R-isomer**, white powder, 93%,  $[\alpha]_D^{20} = +22.95$  ( $c = 53.00$ ).

$^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ ):  $\delta$  10.63 (br, 1H,  $\text{NH}\cdot\text{HCl}$ ), 9.57 (br, 1H,  $\text{NH}\cdot\text{HCl}$ ), 6.55 (s, 1H, *isoxaz*), 4.66 (brs, 1H, *CH*), 3.27-3.22 (m, 2H,  $\text{CH}_2$ -pyrrolidine), 2.43 (s, 3H,  $\text{CH}_3$ ), 2.35-2.33 (m, 1H, *CH*-pyrrolidine), 2.02 (br, 3H,  $\text{CH}_2$ -pyrrolidine).  $^{13}\text{C}$  NMR (125 MHz, DMSO- $d_6$ ):  $\delta$  170.6, 160.1, 101.4, 54.0, 44.4, 29.4, 22.8, 11.9. **MS** (APCI)  $m/z$   $[\text{M}-\text{Cl}+\text{H}]^+$  calculated for  $\text{C}_8\text{H}_{19}\text{N}_2\text{O}$ : 153.1; found: 153.2. Anal. calcd for  $\text{C}_8\text{H}_{13}\text{ClN}_2\text{O}$ : C, 50.93; H, 6.95; N, 14.85. Found: C, 50.87; H, 7.08; N, 14.89.

### **(S)-5-methyl-3-(1-methylpyrrolidin-2-yl)isoxazole (16)**

A 500 mL round bottomed flask was charged with magnetic stirrer and corresponding isoxazole **15** (2.1 g, 10.60 mmol) which was suspended in dichloroethane (250 mL). MeOH (50 mL) was added followed by addition of 30%  $\text{CH}_2\text{O}_{(\text{aq})}$  (10 mL) and  $\text{NaBH}(\text{OAc})_3$  (7.0 g, 33.03 mmol). Then, the resulting mixture was stirred overnight at the ambient temperature. Next, the reaction mixture was concentrated, EtOAc (250 mL) was added and  $\text{K}_2\text{CO}_3$  was added until the pH = 10 was reached (Caution: carbon dioxide evolution!). The reaction mixture was then stirred over  $\text{Na}_2\text{SO}_4$  for ca 10 min filtered and concentrated. The product was purified by distillation yielding **16** (1.52 g, bp. 75-80 °C at 5.5 mmHg) as a colorless liquid (with pyrrolidine odour) which is extremely well soluble in water.

**16-S-isomer**, 82%,  $[\alpha]_D^{20} = -8.00$  ( $c = 60.16$ );

**16-R-isomer**, 83%,  $[\alpha]_D^{20} = +7.86$  ( $c = 60.16$ ).

**<sup>1</sup>H NMR** (500 MHz, DMSO-*d*<sub>6</sub>): δ 6.14 (brs, 1H, *isoxaz*), 3.24-3.19 (t, 1H, *J* = 10.0, *CH-pyrrolidine*), 3.07-3.03 (m, 1H, *CH-pyrrolidine*), 2.36 (s, 3H, *CH<sub>3</sub>-NH*), 2.26-2.19 (m, 1H, *CH-pyrrolidine*), 2.11 (s, 4H, *CH<sub>3</sub> + CH*), 1.84-1.71 (m, 3H, *CH-pyrrolidine*). **<sup>13</sup>C NMR** (125 MHz, DMSO-*d*<sub>6</sub>): δ 169.1, 166.1, 99.7, 61.3, 56.0, 31.7, 22.4, 11.8. **MS** (APCI) *m/z* [M+H]<sup>+</sup> calculated for C<sub>9</sub>H<sub>15</sub>N<sub>2</sub>O: 167.1; found: 167.2. Anal. calcd for C<sub>9</sub>H<sub>14</sub>N<sub>2</sub>O: C, 65.03; H, 8.49; N, 16.85. Found: C, 65.14; H, 8.33; N, 16.94.

ASSOCIATED CONTENT Supporting Information Available: Experimental procedure and characterization of all new compounds (PDF). This material is available free of charge via the Internet at

### Notes and references

- (a) S. Kankala, R. K. Kankala, P. Gundepaka, N. Thota, S. Nerella, M. R. Gangula, H. Guguloth, M. Kagga, R. Vadde, C. S. Vasam, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 1306–1309; (b) B. Frølund, A. T. Jørgensen, L. Tagmose, T. B. Stensbøl, H. T. Vestergaard, C. Engblom, U. Kristiansen, C. Sanchez, P. Krogsgaard-Larsen, T. Liljefors, *J. Med. Chem.*, 2002, **45**, 2454–2468; (c) S. Dadiboyena, A. Nefzi, *J. Med. Chem.*, 2010, **45**, 4697–4707.
- J. J. Talley, D. L. Brown, J. S. Carter, M. J. Graneto, C. M. Koboldt, J. L. Masferrer, W. E. Perkins, R. S. Rogers, A. F. Shaffer, Y. Y. Zhang, B. S. Zweifel, K. Seibert, *J. Med. Chem.*, 2000, **43**, 775–777.
- J. B. Carr, H. G. Durham, D. K. Hass, *J. Med. Chem.*, 1977, **20**, 934–939.
- (a) J. I. Andrés, J. Alcázar, J. M. Alonso, R. M. Alvarez, M. H. Bakker, I. Biesmans, J. M. Cid, A. I. De Lucas, J. Fernández, L. M. Font, K. A. Hens, L. Iturrino, I. Lenaerts, S. Martínez, A. A. Megens, J. Pastor, P. C. M. Vermote, T. Steckler, *J. Med. Chem.*, 2005, **48**, 2054–2071; (b) H. S. Youn, E. J. Lee, J. E. Lee, W.-K. Park, D.-J. Baek, Y. S. Cho, H. Y. Koh, H. Choo, A. N. Pae, *Bull. Korean Chem. Soc.*, 2009, **30**, 1873–1876.
- (a) M. Ma, Y. Cheng, Z. Xu, P. Xu, H. Qu, Y. Fang, T. Xu, L. Wen, *Eur. J. Med. Chem.*, 2007, **42**, 93–98; (b) Ö. Temiz-Arpaci, İ. Yıldız, S. Özkan, F. Kaynak, E. Akı-Şener, İ. Yalçın, *Eur. J. Med. Chem.*, 2008, **43**, 1423–1431.
- (a) W.-T. Li, D.-R. Hwang, C.-P. Chen, C.-W. Shen, C.-L. Huang, T.-W. Chen, C.-H. Lin, Y.-L. Chang, Y.-Y. Chang, Y.-K. Lo, H.-Y. Tseng, C.-C. Lin, J.-S. Song, H.-C. Chen, S.-J. Chen, S. H. Wu, C.-T. Chen, *J. Med. Chem.*, 2003, **46**, 1706–1715; (b) J. Yong, C. Lu, X. Wu, *Med. Chem. Commun.*, 2014, **5**, 968–972.

7. N. Jacobsen, L.-E. K. Pedersen, A. Wengel, *Pestic. Sci.*, 1990, **29**, 95–100.
8. (a) D. S. Garvey, J. T. Wasicak, M. W. Decker, J. D. Brioni, M. J. Buckley, J. P. Sullivan, G. M. Carrera, M. W. Holladay, S. P. Arneric, M. Williams, *J. Med. Chem.*, 1994, **37**, 1055–1059; (b) A. Carenzi, D. Chiarino, D. D. Bella, M. Napoletano, A. Sala, U.S. Patent 4,985,428, Jan. 15, 1991.
9. M. Koufaki, A. Tsatsaroni, X. Alexi, H. Guerrand, S. Zerva, M. N. Alexis, *Bioorg. Med. Chem.*, 2011, **19**, 4841–4850.
10. (a) S. Srivastava, L. K. Bajpai, S. Batra, A. P. Bhaduri, J. P. Maikhuri, G. Gupta, J. D. Dhar, *Bioorg. Med. Chem.*, 1999, **7**, 2607–2613; (b) K.A. Kumar, P. Jayaroopa, *IJPCBS*, 2013, **3**(2), 294–304.
11. (a) F. Hu, M. Szostak, *Adv. Synth. Catal.*, 2015, **357**, 2583–2614.; (b) M. S. Mohamed Ahmed, K. Kobayashi, A. Mori, *Org. Lett.*, 2005, **7**, 4487–4489; (c) T. V. Hansen, P. Wu, V. V. Fokin, *J. Org. Chem.*, 2005, **70**, 7761–7764; (d) S. Grecian, V. V. Fokin, *Angew. Chem. Int. Ed.*, 2008, **47**, 8285; (e) A. V. Dubrovskiy, P. Jain, F. Shi, G. H. Lushington, C. Santini, P. Porubsky and R. C. Larock, *ACS Comb. Sci.*, 2013, **15**, 193–201; (f) R. Huisgen *Angew. Chem. Int. Ed. in English*, 1963, **2**, 565–598; (g) T. M. Vishwanatha, V. V. Sureshbabu, *J. Heterocyclic Chem.*, 2015, **52**, 1823–1833; (h) A. Singhal, S. K. R. Parumala, A. Sharma, R. K. Peddinti *Tetrahedron Letters*, 2015 and references therein.
12. (a) M. A. Weidner-Wells, T. C. Henninger, S. A. Fraga-Spano, C. M. Boggs, M. Matheis, D. M. Ritchie, D. C. Argentieri, M. P. Wachter and D. J. Hlasta, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 4307–4311; (b) S. Dadiboyena, A. Nefzi *Tetrahedron Letters*, 2012, **53**, 2096–2099; (c) D. E. Kizer, R. B. Miller and M. J. Kurth, *Tetrahedron Lett.*, 1999, **40**, 3535–3538; (d) S. Mohammed, R. A. Vishwakarma, S. B. Bharate *RSC Adv.* 2015, **5**, 3470–3473.
13. (a) R. C. F. Jones; S. J. Hollis, J. N. Iley, *Tetrahedron: Asymmetry*, 2000, **11**, 3273–3276; (b) Y. K. Kang, K. J. Shin, K. H. Yoo, K. J. Seo, C. Y. Hong, C.-S. Lee, S. Y. Park, D. J. Kim, S. W. Park *Bioorganic & Medicinal Chemistry Letters*, 2000, **10**, 95–99; (c) R. C. F. Jones; L. E. Seager, M. R. J. Elsegood, *Synlett*, 2011, 211–214; (d) R. C. F. Jones; T. A. Pillainayagam, *Synlett*, 2004, **15**, 2815–2817; (e) R. C. F. Jones, J. P. Bullous, C. C. M. Law, M. R. J. Elsegood, *Chem. Commun.*, 2014, **50**, 1588–1590; (f) M. Falorni, G. Giacomelli, E. Spanu, *Tetrahedron Letters*, 1998, **39**, 9241–9244; (g) M. Falorni, G. Giacomelli, E. Spanedda, *Tetrahedron: Asymmetry*, 1998, **9**, 3039–3046; (h) L. De Luca, G. Giacomelli, Antonella Riu, *J. Org. Chem.*, 2001, **66**, 6823–6825.
14. D. C. Schmitt, L. Lam, J. S. Johnson, *Org. Lett.* 2011, **13**, 5136–5139.

15. (a) Q. F. Jia, P. M. S. Benjamin, J. Huang, Z. Du, X. Zheng, K. Zhang, A. H. Conney, J. Wang, *Synlett* 2013, 79–84. (b) S. Zhu, S. Shi, S. W. Gerritz, *Tetrahedron Lett.* 2011, **52**, 4001–4004.
16. C. C. Lee, R. J. Fitzmaurice, S. Caddick, *Org. Biomol. Chem.* 2009, **7**, 4349–4351.
17. H. Kawai, Y. Sugita, E. Tokunaga, N. Shibata, *Eur. J. Org. Chem.* 2012, **7**, 1295–1298.
18. (a) S. Dadiboyena, J. Xu, A. T. Hamme II, *Tetrahedron Lett.* 2007, **48**, 1295–1298. (b) J. Xu, A. T. Hamme II, *Synlett* 2008, 919–923.
19. M. A. Schmidt, K. Katipally, A. Ramirez, O. Soltani, X. Hou, H. Zhang, B. C. Chen, X. Qian, R. P. Deshpande, *Tetrahedron Lett.* 2012, **53**, 3994–3997.
20. (a) A. O. Abdelhamid, A. A. Fahmi, K. N. M. Halim, *Synthetic Communications*, 2013, **43**, 1101–1126; (b) M. R. Shaaban, T. M. A. Eldebss, A. F. Darweesh, A. M. Farag, *Journal of Heterocyclic Chemistry*, 2008, **45**, 1739–1744.
21. (a) A. Padwa, W. H. Pearson, *Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry toward Heterocycles and Natural Products*, John Wiley & Sons, Ltd, 2002; (b) R. Huisgen *Angew. Chem. Int. Ed. in English*, 1963, **2**, 633–645; (c) L. N. Sobenina, D. N. Tomilin, M. D. Gotsko, I. A. Ushakov, A. I. Mikhaleva, B. A. Trofimov, *Tetrahedron* 2014, **70**, 5168–5174.
22. (a) C. Bryant, I. D. Kerr, M. Debnath, K. K. H. Ang, J. Ratnam, R. S. Ferreira, P. Jaishankar, D. M. Zhao, M. R. Arkin, J. H. McKerrow, L. S. Brinen, A. R. Renslo, *Bioorganic and Medicinal Chemistry Letters*, 2009, **19**, (21), 6218–6221; (b) P. Jones, M. E. Difrancesco, A. Petrocchi, C. L. Carroll, J. Marszalek, B. Czako, R. Johnson, J. Therooff, U.S. Patent US2015252058 (A1), Feb. 27, 2014.
23. L. Hana, B. Zhanga, M. Zhub, J. Yana *Tetrahedron Letters* 2014, **55** (14), 2308–2311.
24. (a) T. Pasinszki, B. Hajgató, B. Havasi, N. P. C. Westwood, *Phys. Chem. Chem. Phys.*, 2009, **11**, 5263–5272; (b) G. Romeo, U. Chiacchio, in *Modern Heterocyclic Chemistry*, Eds. J. Alvarez-Builla, J. J. J. Vaquero, J. Barluenga, Wiley-VCH Verlag & Co., Weinheim, Germany, 2011, 1047–1252.
25. B. Guillaume, K. M. Fiona, B. Renaud, L. Clemens, Q. Laura, T. Stephan U.S. Patent US2014045890 (A1), Feb. 13, 2014.
26. D. N. Reddy, R. Thirupathi, S. Tumminakatti, E. N. Prabhakaran, *Tetrahedron Letters* 53, 2012, 4413–4417.
27. (a) S.P. Arneric, J.P. Sullivan, C.A. Briggs, D. Donnelly-Roberts, D.J. Anderson, J.L. Raszkievicz, M. Hughes, E.D. Cadman, P. Adams, D.S. Garvey, J. Wasicak, M. Williams, *J. Pharmacol. Exp. Ther.*, 1994, **270**, 310–318; (b) D. S. Garvey, J. T. Wasicak, R. L. Elliott, S. A. Lebold, A. Hettinger, G. M. Carrera, N. -H. Lin, Y. He, M.W. Holladay, D. J. Anderson, E. D. Cadman, J. L. Raszkievicz, J. P. Sullivan, S. P. Arneric, *J. Med. Chem.*, 1994, **37**, 4455–4463.

28. (a) A. Plant, F. Stieber, J. Scherkenbeck, P. Lösel, H. Dyker, *Org. Lett.*, 2001, **3**, 3427–3430; (b) I. V. Komarov, A. O. Grigorenko, A. V. Turov, V. P. Khilya, *Russ. Chem. Rev.*, 2004, **73**, 785–810; (c) S. Pellegrino, A. Contini, M. L. Gelmi, L. Lo Presti, R. Soave and Emanuela Erba, *J. Org. Chem.*, 2014, **79**, 3094–3102.
29. In particular, it was been recently demonstrated that terminal 2-oxasole-group is prone to induce  $\beta$ -conformation of the residue: (a) D. Siodłak, M. Staś, M. A. Broda, M. Bujak, T. Lis, *J. Phys. Chem.*, 2014, **118**, 2340–2350; 4,5-Thiasole-based building blocks with (R)-chirality have been used to promote  $\beta$ -turn structures in gramicidin (S)- analogues to construct peptidomimetics with reduced hemolytic activity: (b) B. Legrand, L. Mathieu, A. Lebrun, S. Andriamanarivo, V. Lisowski, N. Masurier, S. Zirah, Y. K. Kang, J. Martinez, L. T. Maillard, *Chem. Eur. J.*, 2014, **20**, 6713–6720.
30. R. A. Hughes, C. J. Moody, *Angew. Chem. Int. Ed.*, 2007, **46**, 7930–7054.
31. P. G. Arnison, M. J. Bibb, G. Bierbaum, A. A. Bowers, T. S. Bugni, G. Bulaj, J. A. Camarero, D. J. Campopiano, G. L. Challis, J. Clardy, P. D. Cotter, D. J. Craik, M. Dawson, E. Dittmann, S. Donadio, P. C. Dorrestein, K.-D. Entian, M. A. Fischbach, J. S. Garavelli, U. Göransson, C. W. Gruber, D. H. Haft, T. K. Hemscheidt, C. Hertweck, C. Hill, A. R. Horswill, M. Jaspars, W. L. Kelly, J. P. Klinman, O. P. Kuipers, A. J. Link, W. Liu, M. A. Marahiel, D. A. Mitchell, G. N. Moll, B. S. Moore, R. Müller, S. K. Nair, I. F. Nes, G. E. Norris, B. M. Olivera, H. Onaka, M. L. Patchett, J. Piel, M. J. T. Reaney, S. Rebuffat, R. P. Ross, H-G. Sahl, E. W. Schmidt, M. E. Selsted, K. Severinov, B. Shen, K. Sivonen, L. Smith, T. Stein, R. D. Süssmuth, J. R. Tagg, G.-L. Tang, A. W. Truman, J. C. Vederas, C. T. Walsh, J. D. Walton, S. C. Wenzel, J. M. Willey, W. A. van der Donk, *Nat. Prod. Rep.*, 2013, **30**, 108–160.
32. K. L. Dunbar, D. A. Mitchell, *J. Am. Chem. Soc.*, 2013, **135**, 8692–8701.
33. R. S. Roy, A. M. Gehring, J. C. Milne, P. J. Belshaw, C. T. Walsh, *Nat. Prod. Rep.*, 1999, **16**, 249–263.
34. E. M. Nolan, C. T. Walsh, *ChemBioChem.*, 2009, **10**, 34–53.
35. V. S. C. Yeh, *Tetrahedron*, 2004, **60**, 11995–12042.
36. For instance see total synthesis of plantazolicin A: (a) S. Banala, P. Ensle, R. D. Süssmuth, *Angew. Chem. Int. Ed.*, 2013, **52**, 9518–9523; microcin B17: (b) R. E. Thompson, F. Collin, A. Maxwell, K. A. Joliffe, R. J. Payne, *Org. Biomol. Chem.*, 2014, **12**, 1570–1578; sansavamide A: (c) M. R. Davis, E. K. Singh, H. Wahyudi, L. D. Alexander, J. B. Kunicki, L. A. Nazarova, K. A. Fairweather, A. M. Giltrap, K. A. Joliffe, S. R. McAlpine, *Tetrahedron*, 2012, **68**, 1029–1051; (R)-telomestatin: (d) T. Doi, M. Yoshida, K. Shin-ya, T. Takahashi, *Org. Lett.*, 2006, **8**, 4165–4167; or dendroamine A: (e) Z. Xia, C. D. Smith, *J. Org. Chem.*, 2001, **66**, 3459–3466.

37. Curiously, epimerization of the AlaIso residue in Ac-Leu-AlaIso-Val-NH<sub>2</sub> (but not in Ac-Leu-Val-AlaIso-NH<sub>2</sub>) would potentially lead to a  $\beta$ -turn structure rather than semi-extended  $\beta$ . This may be the driving force for the partial epimerization observed experimentally.
38. G. Chennakrishnareddy, B. Vasanth, N. Narendra, V. V. Sureshbabu, *Int. J. Pept. Res. Ther.*, 2011, **17**, 185–191.
-



An easy access to a large panel of aminoisoxazoles starting from commonly available amino acids.

